In the battle to fight for pieces of the pie as pharmaceutical spending is likely to decrease, the industry often argues to government that such a decrease will harm innovation.

How well does this message work with government? What do they think of innovation in this area? As welcome or threatening? Given the amount of resource allocated to this area of advocacy, we at HLC think that gaming this argument out further would produce interesting results. Is it possible that a key plank of pharma industry advocacy is actually counterproductive?…